$CLDX

2 stories mentioning CLDXUpdated 8d ago

Every FINWIRES story that references CLDX, newest first.

UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating

Celldex Therapeutics (CLDX) has an average rating of buy and mean price target of $57.53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $30.09, Change: $+0.49, Percent Change: +1.66%

$CLDX

Research59d ago

Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24

Celldex Therapeutics (CLDX) has an average rating of buy and mean price target of $57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CLDX

Track with the FINWIRES app suite

FolioX

Track CLDX in your portfolio

WheelAI

Analyze CLDX options with the wheel strategy

StockInsider

See market sentiment on CLDX